Clinical Trial Update: Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial reports on metabolic effects observed when patients with bipolar disorders switched to aripiprazole.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Metabolic Syndrome

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Bipolar Disorders, Metabolic Complication | Phase 4 | Status: COMPLETED